Verge Genomics and Ferrer Collaborate to Advance ALS Drug Candidate VRG50635 Globally – Draper Decentralized – 9.19.24
Verge Genomics and Ferrer have partnered to co-develop VRG50635, a promising AI-discovered drug for ALS treatment. Ferrer will develop and commercialize the drug in select global markets, while Verge retains U.S. rights as it advances through clinical trials.